JP2010525811A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010525811A5 JP2010525811A5 JP2010506140A JP2010506140A JP2010525811A5 JP 2010525811 A5 JP2010525811 A5 JP 2010525811A5 JP 2010506140 A JP2010506140 A JP 2010506140A JP 2010506140 A JP2010506140 A JP 2010506140A JP 2010525811 A5 JP2010525811 A5 JP 2010525811A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- use according
- treatment
- cancer
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 238000007920 subcutaneous administration Methods 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 8
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 6
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 6
- 230000006907 apoptotic process Effects 0.000 claims description 4
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 3
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 210000000822 natural killer cell Anatomy 0.000 claims description 3
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims 7
- 108091034117 Oligonucleotide Proteins 0.000 claims 5
- 210000004877 mucosa Anatomy 0.000 claims 4
- 238000011394 anticancer treatment Methods 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 2
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000001900 immune effect Effects 0.000 claims 2
- 230000006882 induction of apoptosis Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 206010020843 Hyperthermia Diseases 0.000 claims 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 230000036031 hyperthermia Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000002647 laser therapy Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 238000002428 photodynamic therapy Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000011477 surgical intervention Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 20
- 230000000694 effects Effects 0.000 description 11
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 8
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 208000003950 B-cell lymphoma Diseases 0.000 description 6
- 206010025323 Lymphomas Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000003827 upregulation Effects 0.000 description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 230000006051 NK cell activation Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 230000024704 B cell apoptotic process Effects 0.000 description 1
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 102000006579 Chemokine CXCL10 Human genes 0.000 description 1
- 108010008978 Chemokine CXCL10 Proteins 0.000 description 1
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 230000033540 T cell apoptotic process Effects 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000012820 cell cycle checkpoint Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92758407P | 2007-05-04 | 2007-05-04 | |
| US60/927,584 | 2007-05-04 | ||
| PCT/SE2008/050501 WO2008136748A1 (en) | 2007-05-04 | 2008-04-30 | Tumour growth inhibitory compounds and methods of their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013168777A Division JP5844779B2 (ja) | 2007-05-04 | 2013-08-15 | 腫瘍増殖阻害化合物及びそれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010525811A JP2010525811A (ja) | 2010-07-29 |
| JP2010525811A5 true JP2010525811A5 (enExample) | 2011-06-16 |
| JP5346923B2 JP5346923B2 (ja) | 2013-11-20 |
Family
ID=39943756
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010506140A Expired - Fee Related JP5346923B2 (ja) | 2007-05-04 | 2008-04-30 | 腫瘍増殖阻害化合物及びそれらの使用方法 |
| JP2013168777A Expired - Fee Related JP5844779B2 (ja) | 2007-05-04 | 2013-08-15 | 腫瘍増殖阻害化合物及びそれらの使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013168777A Expired - Fee Related JP5844779B2 (ja) | 2007-05-04 | 2013-08-15 | 腫瘍増殖阻害化合物及びそれらの使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8309529B2 (enExample) |
| EP (2) | EP2573176B1 (enExample) |
| JP (2) | JP5346923B2 (enExample) |
| DK (1) | DK2573176T3 (enExample) |
| ES (1) | ES2581480T3 (enExample) |
| WO (1) | WO2008136748A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2656850B1 (en) * | 2007-10-05 | 2016-07-27 | InDex Pharmaceuticals AB | Oligonucleotides for the treatment or alleviation of edema |
| US20110182880A1 (en) * | 2008-06-18 | 2011-07-28 | Oliver Von Stein | Combination Therapies Against Cancer |
| JP5749651B2 (ja) | 2008-11-04 | 2015-07-15 | インデックス・ファーマシューティカルズ・アクチエボラーグ | 多形核細胞の動員および／または遊走を減少させる化合物および方法 |
| AU2009311753B2 (en) * | 2008-11-04 | 2015-01-15 | Index Pharmaceuticals Ab | Compounds and methods for the treatment of inflammatory diseases of the CNS |
| US9157919B2 (en) * | 2010-12-21 | 2015-10-13 | Index Pharmaceuticals Ab | Method for identifying biologically active oligonucleotides capable of modulating the immune system |
| WO2018174140A1 (ja) * | 2017-03-23 | 2018-09-27 | ナパジェン ファーマ，インコーポレテッド | 癌細胞の接着活性阻害剤 |
| EP3967307A1 (en) | 2020-09-15 | 2022-03-16 | Instytut Hematologii I Transfuzologii | Use of pim kinase inhibitors to augment the efficacy of anti-cd20 antibody-based therapies in hematologic malignancies and non-malignant conditions |
| KR20240006547A (ko) * | 2021-05-04 | 2024-01-15 | 주식회사 애스톤사이언스 | Her2 백신 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6498147B2 (en) | 1992-05-22 | 2002-12-24 | The Scripps Research Institute | Suppression of nuclear factor-κb dependent processes using oligonucleotides |
| EP0772619B2 (en) * | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| WO2000061151A2 (en) * | 1999-04-12 | 2000-10-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| US7534772B2 (en) * | 2000-06-22 | 2009-05-19 | University Of Iowa Research Foundation | Methods for enhancing antibody-induced cell lysis and treating cancer |
| DK2284266T3 (da) * | 2002-11-14 | 2014-01-13 | Thermo Fisher Scient Biosciences Inc | sIRNA-MOLEKYLE MOD TP53 |
| BRPI0416079A (pt) * | 2003-10-30 | 2007-01-02 | Coley Pharm Gmbh | análogos de oligonucleotìdeos de classe c com uma potência imunoestimuladora aumentada |
| MY159370A (en) * | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
| EP2656850B1 (en) * | 2007-10-05 | 2016-07-27 | InDex Pharmaceuticals AB | Oligonucleotides for the treatment or alleviation of edema |
-
2008
- 2008-04-30 US US12/598,674 patent/US8309529B2/en not_active Expired - Fee Related
- 2008-04-30 DK DK12198310.0T patent/DK2573176T3/en active
- 2008-04-30 JP JP2010506140A patent/JP5346923B2/ja not_active Expired - Fee Related
- 2008-04-30 EP EP12198310.0A patent/EP2573176B1/en not_active Not-in-force
- 2008-04-30 ES ES12198310.0T patent/ES2581480T3/es active Active
- 2008-04-30 EP EP08779302A patent/EP2160465B1/en not_active Not-in-force
- 2008-04-30 WO PCT/SE2008/050501 patent/WO2008136748A1/en not_active Ceased
-
2013
- 2013-08-15 JP JP2013168777A patent/JP5844779B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Duan et al. | The Treg/Th17 paradigm in lung cancer | |
| JP2010525811A5 (enExample) | ||
| Lu | Impact of IL-12 in Cancer | |
| Tymoszuk et al. | In situ proliferation contributes to accumulation of tumor‐associated macrophages in spontaneous mammary tumors | |
| Mirantes et al. | Pro-inflammatory cytokines: emerging players regulating HSC function in normal and diseased hematopoiesis | |
| Zhang et al. | Interplay between inflammatory tumor microenvironment and cancer stem cells | |
| Dolcetti et al. | Myeloid-derived suppressor cell role in tumor-related inflammation | |
| Takatsu et al. | IL-5 and eosinophilia | |
| Wu et al. | Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer | |
| Xu et al. | Effect of CRISPR/Cas9-edited PD-1/PD-L1 on tumor immunity and immunotherapy | |
| Spolski et al. | The γ c family of cytokines: fine-tuning signals from IL-2 and IL-21 in the regulation of the immune response | |
| Ribeiro et al. | IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia | |
| Alizadeh et al. | The multifaceted role of Th17 lymphocytes and their associated cytokines in cancer | |
| JPWO2016204193A1 (ja) | 抗がん剤 | |
| Jiang et al. | Different subpopulations of regulatory T cells in human autoimmune disease, transplantation, and tumor immunity | |
| Schakelaar et al. | Cellular immunotherapy for medulloblastoma | |
| Wang et al. | Chimeric antigen receptor T cell therapy and other therapeutics for malignancies: Combination and opportunity | |
| Zou et al. | Chemokines in progression, chemoresistance, diagnosis, and prognosis of colorectal cancer | |
| JP2013511975A5 (enExample) | ||
| Knedla et al. | Developments in the synovial biology field 2006 | |
| Beyzaee et al. | The role of cytokines and vitamin D in vitiligo pathogenesis | |
| Chen et al. | γδ T cells and their roles in immunotherapy: a narrative review | |
| Schweckendiek et al. | Antibodies Targeting the Tumor Necrosis Factor-Like Ligand 1A in Inflammatory Bowel Disease: A New Kid on the (Biologics) Block? | |
| Hardan et al. | Treatment with interferon alpha prior to discontinuation of imatinib in patients with chronic myeloid leukemia | |
| Botta et al. | New Immunotherapy Approaches for Preventing Cancer |